BioInvent International AB (STU:BIX) Cyclically Adjusted FCF per Share: €-0.63 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:BIX BioInvent International AB STU:BIX
51 GF Score
Price €2.04
GF Value €4.40
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is BioInvent International AB Cyclically Adjusted FCF per Share?

BioInvent International AB STU:BIX -0.97% 51 Cyclically Adjusted FCF per Share is €-0.63 as of Mar. 2026. GuruFocus rates STU:BIX with a GF Score™ of 51/100 and a GF Value™ of €4.40 (Possible Value Trap). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

BioInvent International AB's adjusted free cash flow per share for the three months ended in Mar. 2026 was €-0.188. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €-0.63 for the trailing ten years ended in Mar. 2026.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 14.50% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was 15.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of BioInvent International AB was 17.80% per year. The lowest was 14.10% per year. And the median was 14.50% per year.

As of today (2026-08-12), BioInvent International AB's current stock price is €2.035. BioInvent International AB's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was €-0.63. BioInvent International AB's Cyclically Adjusted Price-to-FCF of today is .


BioInvent International AB  (STU:BIX) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


BioInvent International AB Cyclically Adjusted FCF per Share Related Terms


BioInvent International AB Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for BioInvent International AB's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioInvent International AB Cyclically Adjusted FCF per Share Chart

BioInvent International AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.39 -0.94 -0.84 -0.70 -0.62

BioInvent International AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.63 -0.61 -0.60 -0.62 -0.63

STU:BIX vs VRTX, REGN, RVMD: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, BioInvent International AB's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioInvent International AB Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioInvent International AB's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where BioInvent International AB's Cyclically Adjusted Price-to-FCF falls into.


STU:BIX
51GF Score
BioInvent International AB STU:BIX
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioInvent International AB Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, BioInvent International AB's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.188/133.5600*133.5600
=-0.188

Current CPI (Mar. 2026) = 133.5600.

BioInvent International AB Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 -0.262 101.019 -0.346
201609 -0.251 101.138 -0.331
201612 -0.222 102.022 -0.291
201703 -0.081 102.022 -0.106
201706 -0.199 102.752 -0.259
201709 -0.253 103.279 -0.327
201712 -0.235 103.793 -0.302
201803 -0.227 103.962 -0.292
201806 -0.266 104.875 -0.339
201809 -0.238 105.679 -0.301
201812 -0.259 105.912 -0.327
201903 -0.273 105.886 -0.344
201906 -0.174 106.742 -0.218
201909 -0.110 107.214 -0.137
201912 -0.132 107.766 -0.164
202003 -0.163 106.563 -0.204
202006 -0.138 107.498 -0.171
202009 -0.096 107.635 -0.119
202012 0.069 108.296 0.085
202103 -0.123 108.360 -0.152
202106 -0.111 108.928 -0.136
202109 -0.106 110.338 -0.128
202112 -0.131 112.486 -0.156
202203 -0.134 114.825 -0.156
202206 -0.104 118.384 -0.117
202209 0.244 122.296 0.266
202212 -0.109 126.365 -0.115
202303 -0.111 127.042 -0.117
202306 -0.115 129.407 -0.119
202309 -0.140 130.224 -0.144
202312 -0.102 131.912 -0.103
202403 -0.091 132.205 -0.092
202406 -0.167 132.716 -0.168
202409 -0.133 132.304 -0.134
202412 -0.131 132.987 -0.132
202503 -0.170 132.825 -0.171
202506 0.090 133.699 0.090
202509 -0.147 133.480 -0.147
202512 -0.128 133.390 -0.128
202603 -0.188 133.560 -0.188

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of €-0.63 mean?
BioInvent International AB (STU:BIX) has a Cyclically Adjusted FCF per Share of €-0.63 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on BioInvent International AB and its competitors.
Is BioInvent International AB's Cyclically Adjusted FCF per Share too high?
BioInvent International AB's current Cyclically Adjusted FCF per Share is €-0.63. Overall, BioInvent International AB has a GF Score™ of 51/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does BioInvent International AB's Cyclically Adjusted FCF per Share compare to VRTX and REGN?
BioInvent International AB's Cyclically Adjusted FCF per Share of €-0.63 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on BioInvent International AB and its competitors. BioInvent International AB's current Cyclically Adjusted FCF per Share is €-0.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioInvent International AB stock overvalued right now?
Based on GuruFocus' analysis, BioInvent International AB (STU:BIX) is currently considered Possible Value Trap. The stock's GF Value™ is €4.40, compared to a current price of €2.04 — trading 53.8% below its estimated fair value. The current Cyclically Adjusted FCF per Share is €-0.63. BioInvent International AB's overall GF Score™ is 51/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For BioInvent International AB (STU:BIX), the current Cyclically Adjusted FCF per Share is €-0.63 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BioInvent International AB (STU:BIX) Overvalued in 2026?

Based on GuruFocus' analysis, BioInvent International AB stock appears to be undervalued. The current stock price of €2.04 is trading 53.8% below its estimated GF Value™ of €4.40. GuruFocus considers BioInvent International AB to be Possible Value Trap.

Key valuation signals for STU:BIX:

  • Cyclically Adjusted FCF per Share: €-0.63
  • GF Value™: €4.40 vs. price of €2.04 (53.8% below fair value)
  • GF Score™: 51/100 with 4 warning signs

No single metric tells the full story. See the STU:BIX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


BioInvent International AB Business Description

Other Exchanges BINV:Sweden0H22:UK
Address Ideongatan 1, Lund, SWE, SE-223 70
BioInvent International AB is a clinical-stage biotech company. It discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently four drug candidates in five ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors, respectively. The company's validated, proprietary F.I.R.S.T technology platform identifies both targets and the antibodies that bind to them, generating many new drug candidates to fuel the company's clinical development pipeline and providing licensing and partnering opportunities. The company's pipeline portfolio comprises BI-1206, an antagonistic blocking antibody for the treatment of non-Hodgkin's lymphoma, and BI-1808 and BI-1910 (anti-TNFR2) for solid cancers.
51GF Score

Get the complete analysis for STU:BIX

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.04
Price
€4.40
GF Value